Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2011-05-02 17:40 |
VIVALIS DOCUMENT DE REFERENCE
|
English | 117.5 KB | ||
| 2011-04-26 17:40 |
VIVALIS STRENGTHENS ITS ANTIBODY DISCOVERY PLATFORM
|
English | 325.7 KB | ||
| 2011-04-26 17:40 |
VIVALIS RENFORCE SA PLATEFORME DE DECOUVERTE D'ANTICORPS
|
French | 318.4 KB | ||
| 2011-04-19 17:40 |
VIVALIS ANNOUNCED THE CONDUCTION BY KAKETSUKEN OF HUMAN CLINICAL STUDIES WITH A…
|
English | 105.7 KB | ||
| 2011-04-19 17:40 |
VIVALIS ANNONCE LA REALISATION PAR KAKETSUKEN D'ESSAIS CLINIQUES CHEZ l'HOMME A…
|
French | 82.7 KB | ||
| 2011-04-12 17:40 |
VIVALIS SIGNS AN EB66® CELL LINE RESEARCH AGREEMENT FOR HUMAN VACCINE PRODUCTI…
|
English | 94.2 KB | ||
| 2011-04-12 17:40 |
VIVALIS SIGNE UN NOUVEL ACCORD DE RECHERCHE DE LA LIGNÉE CELLULAIRE EB66® POUR …
|
French | 88.2 KB | ||
| 2011-04-06 17:45 |
VIVALIS ACTIONS ET DROITS DE VOTE MARS 2011
|
English | 50.8 KB | ||
| 2011-03-28 07:45 |
VIVALIS announced annual results for year 2010 and its strategic outlook
|
English | 86.0 KB | ||
| 2011-03-28 07:45 |
VIVALIS annonce ses résultats 2010 et ses perspectives stratégiques
|
French | 86.7 KB | ||
| 2011-03-22 17:40 |
VIVALIS ANNONCE UNE NOUVELLE LICENCE DE RECHERCHE AVEC OKAIROS SRL
|
French | 472.7 KB | ||
| 2011-03-22 17:40 |
VIVALIS ANNOUNCES A FIRST EB66® CELL LINE RESEARCH LICENSE WITH OKAIROS SRL
|
English | 474.0 KB | ||
| 2011-03-08 17:41 |
VIVALIS ACTIONS ET DROITS DE VOTE
|
English | 50.7 KB | ||
| 2011-02-14 17:40 |
VIVALIS ET LE SINGAPORE IMMUNOLOGY NETWORK DE A*STAR DECOUVRENT UN TRAITEMENT P…
|
French | 182.0 KB | ||
| 2011-02-14 17:40 |
POTENTIAL TREATMENT FOR CHIKUNGUNYA DISCOVERED BY COLLABORATION BETWEEN VIVALIS…
|
English | 191.2 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
